A clinical-stage biotechnology company developing native human monoclonal antibodies to treat intractable infectious diseases.
Focused on advancing calpurbatug (TRL1068), an investigational monoclonal antibody being evaluated for chronic prosthetic joint infections (PJI).
Leadership & Board
Currently, no data available
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$9M
Total Amount Raised$9M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$9M
Latest Funding Amount$9M
Latest Funding RoundSeries C
Latest Funding RoundSeries C
Post-Money Valuation―
Post-Money Valuation―
Funding Round
Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Jul 16, 2026
Series C
$9.00M
―
Similar Companies
A snapshot of private companies similar to Trellis Bioscience, helping you discover and navigate related company profiles.